PMC:7571312 / 34239-35017
Annnotations
LitCovid-PD-FMA-UBERON
| Id | Subject | Object | Predicate | Lexical cue | fma_id |
|---|---|---|---|---|---|
| T84 | 494-500 | Body_part | denotes | plasma | http://purl.org/sig/ont/fma/fma62970 |
LitCovid-PD-MONDO
| Id | Subject | Object | Predicate | Lexical cue | mondo_id |
|---|---|---|---|---|---|
| T88 | 105-109 | Disease | denotes | SARS | http://purl.obolibrary.org/obo/MONDO_0005091 |
| T89 | 167-171 | Disease | denotes | SARS | http://purl.obolibrary.org/obo/MONDO_0005091 |
| T90 | 308-312 | Disease | denotes | SARS | http://purl.obolibrary.org/obo/MONDO_0005091 |
| T91 | 378-382 | Disease | denotes | SARS | http://purl.obolibrary.org/obo/MONDO_0005091 |
| T92 | 643-647 | Disease | denotes | SARS | http://purl.obolibrary.org/obo/MONDO_0005091 |
| T93 | 769-777 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
LitCovid-PD-CLO
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T363 | 494-500 | http://purl.obolibrary.org/obo/UBERON_0001969 | denotes | plasma |
| T364 | 578-579 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
| T365 | 661-664 | http://purl.obolibrary.org/obo/CLO_0051582 | denotes | has |
| T366 | 717-718 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
LitCovid-PD-CHEBI
| Id | Subject | Object | Predicate | Lexical cue | chebi_id |
|---|---|---|---|---|---|
| T558 | 72-86 | Chemical | denotes | peptidomimetic | http://purl.obolibrary.org/obo/CHEBI_63175 |
| T559 | 87-97 | Chemical | denotes | inhibitors | http://purl.obolibrary.org/obo/CHEBI_35222 |
| T560 | 136-138 | Chemical | denotes | IV | http://purl.obolibrary.org/obo/CHEBI_74327 |
| T561 | 290-300 | Chemical | denotes | inhibitors | http://purl.obolibrary.org/obo/CHEBI_35222 |
| T562 | 414-423 | Chemical | denotes | antiviral | http://purl.obolibrary.org/obo/CHEBI_22587 |
LitCovid-sentences
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T233 | 0-203 | Sentence | denotes | This report details the efforts to identify irreversible and reversible peptidomimetic inhibitors of the SARS CoV-1 3CLpro as potential IV agents for the treatment of SARS and other coronavirus diseases. |
| T234 | 204-320 | Sentence | denotes | Two classes, acyloxymethylketones and hydroxymethylketones, were discovered as potent inhibitors of the SARS 3CLpro. |
| T235 | 321-431 | Sentence | denotes | The hydroxymethylketone derivative 4 demonstrated potent SARS CoV-1 inhibition in 3CLpro and antiviral assays. |
| T236 | 432-778 | Sentence | denotes | Additionally, 4 possesses acceptable solubility, stability in plasma, and low in vitro and in vivo clearances suitable for further development as a coronavirus treatment.49 Importantly, the potent inhibition of SARS CoV-2 3CLpro has prompted further preclinical investigations of 4 as a potential therapeutic treatment for patients with COVID-19. |
LitCovid-PubTator
| Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
|---|---|---|---|---|---|
| 879 | 105-113 | Species | denotes | SARS CoV | Tax:694009 |
| 880 | 378-386 | Species | denotes | SARS CoV | Tax:694009 |
| 881 | 580-591 | Species | denotes | coronavirus | Tax:11118 |
| 882 | 643-653 | Species | denotes | SARS CoV-2 | Tax:2697049 |
| 883 | 755-763 | Species | denotes | patients | Tax:9606 |
| 884 | 217-237 | Chemical | denotes | acyloxymethylketones | |
| 885 | 242-262 | Chemical | denotes | hydroxymethylketones | |
| 886 | 308-319 | Chemical | denotes | SARS 3CLpro | |
| 887 | 325-344 | Chemical | denotes | hydroxymethylketone | |
| 888 | 182-202 | Disease | denotes | coronavirus diseases | MESH:D018352 |
| 889 | 769-777 | Disease | denotes | COVID-19 | MESH:C000657245 |